lenalidomide has been researched along with fludarabine in 14 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (fludarabine) | Trials (fludarabine) | Recent Studies (post-2010) (fludarabine) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 3,452 | 812 | 1,415 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 12 (85.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Bazargan, A; Tam, CS | 1 |
| de Rezende, LC; Guimarães, MC; Rangel, LB; Silva, IV | 1 |
| Bloor, A; Bosch, F; Bühler, A; Chanan-Khan, AA; Coutré, S; Dreisbach, L; Ferrajoli, A; Frankfurt, O; Furman, RR; Gobbi, M; Gribben, JG; Hallek, M; Heerema, NA; Hillmen, P; Hurd, DD; Kimby, E; Mahadevan, D; Moutouh-de Parseval, L; Sekeres, MA; Shah, S; Stilgenbauer, S; Uharek, L; Wendtner, CM; Zhang, J | 1 |
| Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Kröger, N; Lanza, F; Lemoli, R; Malard, F; Mikala, G; Mohty, M; Selleslag, D; Worel, N | 1 |
| Fabiano, AJ; Fenstermaker, RA; Qiu, J; Rigual, D | 1 |
| Chennupati, S; Golla, M; Nalla, S; Rangasamy, M; Thappali, S; Vakkalanka, S; Veeraraghavan, S; Viswanadha, S | 1 |
| Azzollini, K; Bejot, C; Bhattacharyya, PK; Chow, KF; Feldman, T; Foon, KA; Gadaleta, G; Goy, A; Howlett, C; Kdiry, S; Mato, AR; Mrkulic, M; Pascual, LN; Porter, D; Schuster, SJ; Strelec, L; Svoboda, J; Valentinetti, M; Yannotti, K; Zenreich, J | 1 |
| Hogan, JJ; Weiss, BM | 1 |
| Belsito, V; Carella, AM; Cortellezzi, A; Cuneo, A; De Propris, MS; Ferretti, A; Foà, R; Guarini, AR; Liberati, AM; Marinelli, M; Mauro, FR; Molica, S; Nanni, M; Orlando, SM; Paoloni, F; Rizzi, R; Spriano, M; Tosi, P; Vignetti, M; Zaja, F | 1 |
| Schmidt, C | 1 |
| Catakovic, K; Egle, A; Gassner, FJ; Geisberger, R; Girschikofsky, M; Greil, R; Hartmann, TN; Lang, A; Melchardt, T; Petzer, A; Pleyer, L; Steurer, M; Thaler, J; Voskova, D; Weiss, L; Zaborsky, N | 1 |
| Cheng, Z; Feng, L; He, F; Wei, R; Wu, Y; Xiao, M; Zhao, G | 1 |
4 review(s) available for lenalidomide and fludarabine
| Article | Year |
|---|---|
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Regulatory T cell as a target for cancer therapy.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Humans; Immunotherapy; Lenalidomide; Mice; Models, Animal; Myeloablative Agonists; Neoplasms; T-Lymphocytes, Regulatory; Thalidomide; Vidarabine | 2010 |
Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulins; Immunosuppressive Agents; Kidney Diseases; Lenalidomide; Melphalan; Oligopeptides; Paraproteinemias; Pentostatin; Rituximab; Thalidomide; Vidarabine | 2016 |
Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature.
Topics: B-Cell Maturation Antigen; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin D; Immunologic Factors; Immunotherapy, Adoptive; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Receptors, Chimeric Antigen; Recurrence; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2022 |
5 trial(s) available for lenalidomide and fludarabine
| Article | Year |
|---|---|
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Dose-Response Relationship, Immunologic; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Tumor Lysis Syndrome; Vidarabine | 2012 |
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Compassionate Use Trials; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Vidarabine | 2012 |
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Rate; Thalidomide; Vidarabine | 2015 |
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome; Vidarabine | 2017 |
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Consolidation Chemotherapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Hematologic Diseases; Humans; Immunity, Cellular; Immunologic Memory; Immunotherapy; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Remission Induction; Rituximab; T-Lymphocyte Subsets; Thalidomide; Treatment Outcome; Vidarabine | 2018 |
5 other study(ies) available for lenalidomide and fludarabine
| Article | Year |
|---|---|
New agents for the treatment of genetically high-risk chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Cyclophosphamide; Drug Therapy; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; Risk; Rituximab; Thalidomide; Treatment Outcome; Vidarabine | 2010 |
Tumoral Bing-Neel Syndrome presenting as a cerebellar mass.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Brain Edema; Cerebellar Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Nervous System Diseases; Neurosurgical Procedures; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2013 |
Simultaneous quantification of idelalisib, fludarabine and lenalidomide in rat plasma by using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass spectrometry.
Topics: Animals; Chromatography, High Pressure Liquid; Drug Stability; Lenalidomide; Male; Purines; Quinazolinones; Rats; Rats, Wistar; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Thalidomide; Vidarabine | 2014 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
The struggle to do no harm in clinical trials.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD19; Child; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Inflammation; Lenalidomide; Male; Neoplasms; Nivolumab; Prognosis; Programmed Cell Death 1 Receptor; Risk Management; T-Lymphocytes; Thalidomide; Treatment Outcome; Vidarabine | 2017 |